NICEVIVA
MONOGRAPH SPEC LATEST 2026

Chamomile

BOTANICALS · Evidence Monograph

Chamomile is an evidence-graded botanicals monograph evaluated across 30 peer-reviewed PubMed studies (2 meta-analyses, 3 systematic reviews, and 7 randomized controlled trials, encompassing n = 5,323 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 2 Meta · 3 Systematic Reviews
Randomized Trials (RCT) 7 RCTs (6 Double-Blind)
Cumulative Participants n = 5,323
Reported Trial Dosages 100 mg · 500 mg · 1 g/day
Trial Duration Range 6 weeks · 21 days · 12 weeks
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (100 mg · 500 mg · 1 g/day) over a structured 6 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
anxiety (PubMed clinical endpoint)
pain (PubMed clinical endpoint)
sleep (PubMed clinical endpoint)
01

What Is Chamomile & Why Does Form Matter?

Chamomile is classified under BOTANICALS and has been investigated across 30 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (100 mg, 500 mg, 1 g/day).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Chamomile frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (7 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Chamomile acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Chamomile an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 2 meta-analyses, 3 systematic reviews, and 7 randomized controlled trials (6 double-blind, n = 5,323 total participants).

Representative peer-reviewed findings include: • PMID:36940841 (2023) — "Non-pharmacological interventions in the treatment of rheumatoid arthritis: A systematic review and meta-analysis." (Further clinical trials that are well-designed, adequately powered, and sufficiently report ACR improvement criteria or EULAR response criteria outcomes are needed to confirm the efficacy of these therapies.) • PMID:35311615 (2022) — "Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce." (RESULTS: Amongst nutraceuticals with Grade A evidence,) • PMID:27000311 (2016) — "Dietary supplements for dysmenorrhoea." (Conventional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and oral contraceptive pills (OCPs), which both reduce myometrial activity (contractions of the uterus).)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)OR Effect Size & 95% CI DistributionEstimate (95% CI)PMID 270003115.44PMID 367508491.92 (1.43–2.58)0.2Null (1)5Metric: OR
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 100 mg · 500 mg · 1 g/day over 6 weeks · 21 days · 12 weeks · 4 weeks. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Chamomile, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (100 mg · 500 mg · 1 g/day) and re-evaluate efficacy after 6 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 18 Quantitative Analyses

01
META-ANALYSIS Autoimmunity reviews (2023) PMID: 36940841 ↗
Non-pharmacological interventions in the treatment of rheumatoid arthritis: A systematic review and meta-analysis.
Clinical Trial Synthesis 2023 Meta-Analysis published in Autoimmunity reviews; statistical significance reported at p = 0.04. Key conclusion: Further clinical trials that are well-designed, adequately powered, and sufficiently report ACR improvement criteria or EULAR response criteria outcomes are needed to confirm the efficacy of these therapies.
View Original PubMed Abstract ↓

PURPOSE: To investigate the role of non-pharmaceutical therapies on disease activity in rheumatoid arthritis through systematic review and meta-analysis. METHODS: A review of Pubmed, EMBASE, Web of Science, and the Cochrane Library was performed from inception until March 26, 2019. Only randomized controlled trials which assessed oral, non-pharmacological interventions (e.g. diets, vitamins, oils, herbal remedies, fatty acids, supplements, etc.) in adult patients with rheumatoid arthritis, that presented clinically-relevant outcomes (defined as pain, fatigue, disability, joint counts, and/or disease indices) were included in our meta-analysis. Data were analyzed as mean differences between active and placebo and forest plots were performed. Heterogeneity was evaluated using I-squared statistics while funnel plots and Cochrane's risk of bias assessment evaluated bias. RESULTS: 8170 articles were identified in the search and 51 were RCTs were included. The mean difference in DAS28 was significantly improved in experimental group treated with diet (-0.46 [-0.91, -0.02], p = 0.04), zinc sulfate, copper sulphate, selenium, potassium, lipoic acid, turmeric, pomegranate extract, chamomile, and cranberry extract supplements (-0.77 [-1.17, -0.38], p < 0.001), A, B6, C, D, E, and K vitamins (-0.52 [-0.74, -0.29], p < 0.001), and fatty acids (-0.19 [-0.36, -0.01], p = 0.03). Other clinical metrics such as SJC, TJC, HAQ, SDAI, ACR20, and self-reported pain were decreased in the treatment groups. There was significant reporting bias in the studies. CONCLUSION: Some non-pharmacological therapies may modestly improve some clinical outcomes in patients with rheumatoid arthritis. Many identified studies lacked full reporting. Further clinical trials that are well-designed, adequately powered, and sufficiently report ACR improvement criteria or EULAR response criteria outcomes are needed to confirm the efficacy of these therapies.

02
CLINICAL STUDY The world journal of biological psychiatry (2022) PMID: 35311615 ↗
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
Clinical Trial Synthesis 2022 Meta-Analysis published in The world journal of biological psychiatry. Key conclusion: RESULTS: Amongst nutraceuticals with Grade A evidence,
View Original PubMed Abstract ↓

OBJECTIVES: The therapeutic use of nutrient-based 'nutraceuticals' and plant-based 'phytoceuticals' for the treatment of mental disorders is common; however, despite recent research progress, there have not been any updated global clinical guidelines since 2015. To address this, the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Disorders (CANMAT) convened an international taskforce involving 31 leading academics and clinicians from 15 countries, between 2019 and 2021. These guidelines are aimed at providing a definitive evidence-informed approach to assist clinicians in making decisions around the use of such agents for major psychiatric disorders. We also provide detail on safety and tolerability, and clinical advice regarding prescription (e.g. indications, dosage), in addition to consideration for use in specialised populations. METHODS: The methodology was based on the WFSBP guidelines development process. Evidence was assessed based on the WFSBP grading of evidence (and was modified to focus on Grade A level evidence - meta-analysis or two or more RCTs - due to the breadth of data available across all nutraceuticals and phytoceuticals across major psychiatric disorders). The taskforce assessed both the 'level of evidence' (LoE) (i.e. meta-analyses or RCTs) and the assessment of the direction of the evidence, to determine whether the intervention was 'Recommended' (+++), 'Provisionally Recommended' (++), 'Weakly Recommended' (+), 'Not Currently Recommended' (+/-), or 'Not Recommended' (-) for a particular condition. Due to the number of clinical trials now available in the field, we firstly examined the data from our two meta-reviews of meta-analyses (nutraceuticals conducted in 2019, and phytoceuticals in 2020). We then performed a search of additional relevant RCTs and reported on both these data as the primary drivers supporting our clinical recommendations. Lower levels of evidence, including isolated RCTs, open label studies, case studies, preclinical research, and interventions with only traditional or anecdotal use, were not assessed. RESULTS: Amongst nutraceuticals with Grade A evidence,

03
CLINICAL STUDY The Cochrane database of systematic reviews (2016) PMID: 27000311 ↗
Dietary supplements for dysmenorrhoea.
Clinical Trial Synthesis 2016 Randomized Controlled Trial (RCT) published in The Cochrane database of systematic reviews involving n = 3,101 participants (OR 5.44). Key conclusion: Conventional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and oral contraceptive pills (OCPs), which both reduce myometrial activity (contractions of the uterus).
View Original PubMed Abstract ↓

BACKGROUND: Dysmenorrhoea refers to painful menstrual cramps and is a common gynaecological complaint. Conventional treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and oral contraceptive pills (OCPs), which both reduce myometrial activity (contractions of the uterus). A suggested alternative approach is dietary supplements. We used the term 'dietary supplement' to include herbs or other botanical, vitamins, minerals, enzymes, and amino acids. We excluded traditional Chinese medicines. OBJECTIVES: To determine the efficacy and safety of dietary supplements for treating dysmenorrhoea. SEARCH METHODS: We searched sources including the Cochrane Gynaecology and Fertility Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, AMED, PsycINFO (all from inception to 23 March 2015), trial registries, and the reference lists of relevant articles. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of dietary supplements for moderate or severe primary or secondary dysmenorrhoea. We excluded studies of women with an intrauterine device. Eligible comparators were other dietary supplements, placebo, no treatment, or conventional analgesia. DATA COLLECTION AND ANALYSIS: Two review authors independently performed study selection, performed data extraction and assessed the risk of bias in the included trials. The primary outcomes were pain intensity and adverse effects. We used a fixed-effect model to calculate odds ratios (ORs) for dichotomous data, and mean differences (MDs) or standardised mean differences (SMDs) for continuous data, with 95% confidence intervals (CIs). We presented data that were unsuitable for analysis either descriptively or in additional tables. We assessed the quality of the evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods. MAIN RESULTS: We included 27 RCTs (3101 women). Most included studies were conducted amongst cohorts of students with primary dysmenorrhoea in their late teens or early twenties. Twenty-two studies were conducted in Iran and the rest were performed in other middle-income countries. Only one study address

04
RANDOMIZED TRIAL (RCT) Journal of food and drug analysis (2025) PMID: 41525193 ↗
Effects of chamomile and -theanine beverage on menstrual pain, menstrual symptoms, mood, and sleep quality in young women experiencing primary dysmenorrhea: A randomized, double-blind, placebo-controlled study.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Journal of food and drug analysis involving n = 15 participants; statistical significance reported at p = 0.001. Key conclusion: Meanwhile, non-CTT consumption significantly reduced ( p < 0.05) the severity of complexation, neuroticism, and confusion in the control group.
View Original PubMed Abstract ↓

Primary dysmenorrhea is one of the most common complaints among young women. This study aimed to evaluate the effects of chamomile and 1-theanine beverage intake on menstrual symptoms, pain intensity, mood, and sleep quality in young adult females with primary dysmenorrhea, using a two-phase continuous study design. In the first phase, a cross-sectional study was conducted to assess the prevalence of primary dysmenorrhea. In the second phase, participants were randomly assigned to either the intervention group (n = 15), which consumed chamomile and 1-theanine beverage (CTT), or the control group (n = 15), which consumed chamomile-flavored beverage (non-CTT). Beverages were consumed daily for five consecutive days, starting two days before the expected onset of menstruation and continuing through the first three days of menstruation. Compared to baseline values, consumption of CTT significantly reduced ( p < 0.001) visual analog scale and numerical rating scale values by 57.17% and 55.46%, respectively. Additionally, CTT intake led to significant reductions ( p < 0.05) in the severity of lower abdominal pain, loss of appetite, backpain, complexation, stomachache, body pain, depression, and irritability by 52.86%, 47.24%, 56.29%, 31.03%, 43.14%, 42.52%, 49.46%, 45.11%, respectively. CTT consumption also significantly decreased ( p < 0.05) daytime dysfunction by 31.97% compared to baseline. Meanwhile, non-CTT consumption significantly reduced ( p < 0.05) the severity of complexation, neuroticism, and confusion in the control group. The CTT beverage could be a potential alternative for managing primary dysmenorrhea. Further studies with longer durations are warranted to assess its potential long-term physiological effects.

05
CLINICAL STUDY Zhonghua nan ke xue = National journal of andrology (2024) PMID: 40783833 ↗
[Sertraline hydrochloride combined with compound chamomile lidocaine gel for the treatment of premature ejaculation].
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Zhonghua nan ke xue = National journal of andrology involving n = 80 participants; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: Sertraline hydrochloride combined with compound chamomile lidocaine gel is definitely effective in the treatment of PE, which can significantly improve the patients' quality of sexual life, with a high safety and low incidence of adverse reactions.
View Original PubMed Abstract ↓

OBJECTIVE: To investigate the effect of sertraline hydrochloride combined with compound chamomile lidocaine gel in the treatment of premature ejaculation (PE). METHODS: We selected 80 cases of PE treated in our hospital from June 2021 to May 2023 and equally randomized them into a control and an observation group, the former medicated with compound chamomile lidocaine gel while the latter with sertraline hydrochloride in addition, both for 6 weeks. We recorded and compared the intravaginal ejaculation latency time (IELT), the number of successful sexual intercourses per week, the Premature Ejaculation Diagnostic Tool (PEDT) scores, and the incidence of adverse reactions between the two groups of patients. RESULTS: After the treatment, the IELT was significantly longer ([5.39 ± 1.17] vs [2.49 ± 0.73] min, P< 0.05), the weekly number of successful sexual intercourses remarkably higher (1.82 ± 0.45 vs 0.93 ± 0.19, P< 0.05) and the PEDT scores markedly lower (7.42 ± 2.04 vs 9.85 ± 2.36, P< 0.05) in the observation than in the control group, but no statistically significant differences were observed in the baseline PEDT scores or the incidence of adverse reactions between the two groups (P> 0.05). CONCLUSION: Sertraline hydrochloride combined with compound chamomile lidocaine gel is definitely effective in the treatment of PE, which can significantly improve the patients' quality of sexual life, with a high safety and low incidence of adverse reactions.

06
RANDOMIZED TRIAL (RCT) Explore (New York, N.Y.) (2025) PMID: 40440968 ↗
Topical chamomile oil as a novel therapeutic intervention for diabetic neuropathy: A randomized double-blind controlled clinical trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Explore (New York, N.Y.) involving n = 72 participants; statistical significance reported at p = 0.05 (MD -1.14). Key conclusion: CONCLUSION: Topical chamomile oil significantly alleviates neuropathic symptoms in diabetic patients, offering a safe and adjunctive therapeutic option.
View Original PubMed Abstract ↓

BACKGROUND: Diabetic neuropathy, a prevalent complication of diabetes mellitus, significantly impairs quality of life due to chronic pain and sensory deficits. Conventional pharmacotherapies, while effective, are often limited by systemic adverse effects. Chamomile (Matricaria chamomilla L.) oil, renowned for its anti-inflammatory, antioxidant, and analgesic properties, presents a promising topical alternative for mitigating neuropathic symptoms. OBJECTIVE: This study aimed to evaluate the efficacy of topical chamomile oil in improving neuropathy indices among patients with controlled diabetes, as measured by validated clinical tools. METHODS: A randomized, double-blind, placebo-controlled trial was conducted involving 72 participants with diabetic neuropathy. Participants were allocated to either the intervention group (chamomile oil) or the control group (placebo), with both groups continuing standard gabapentin therapy. Neuropathy outcomes were assessed using Neurothesiometer scores, the Michigan Neuropathy Screening Instrument (MNSI), and the DN4 questionnaire at baseline and post-intervention. ANCOVA was employed to analyze intergroup differences, adjusting for baseline covariates. RESULTS: The chamomile oil group exhibited statistically significant improvements in neuropathy indices compared to the placebo group (p < 0.05). Post-intervention, reductions in Neurothesiometer scores (mean difference: -1.14 ± 0.42), MNSI (-1.89 ± 0.31), and DN4 (-1.97 ± 0.28) were observed in the intervention group, with no comparable changes in controls. ANCOVA confirmed the robustness of these findings (F = 6.72, p = 0.012). CONCLUSION: Topical chamomile oil significantly alleviates neuropathic symptoms in diabetic patients, offering a safe and adjunctive therapeutic option. Its mechanism may involve modulation of oxidative stress and inflammatory pathways, warranting further investigation into long-term benefits and molecular targets. TRIAL REGISTRATION: This trial was registered at the Iranian Registry of Clinical Trials (IRCT), registration number IRCT20240611062090N1. The full protocol is available at www.irct.ir.

07
CLINICAL STUDY International wound journal (2025) PMID: 40258627 ↗
Assessment of the Effect of Topical 'Scrophularia Striata' Solution on Healing of Peristomal Wound in Patients Referring to Tehran Ostomy Association, 2023.
Clinical Trial Synthesis 2025 Clinical Study published in International wound journal; statistical significance reported at p = 0.001. Key conclusion: The results of the study indicate that the topical solution of Scrophularia Striata has been effective and more efficient in improving peristomal skin wounds compared to other routine treatments in these patients.
View Original PubMed Abstract ↓

This study investigates the effects of topical solution of Scrophularia Striata in the healing process of peristomal skin wounds in patients attending the Stoma. One hundred participants from June 2023 to September 2023 were selected using convenience sampling and randomly assigned to two groups (experimental and control) in blocks using software. The experimental group was instructed to apply the topical solution of Scrophularia Striata once daily, saturating the ulcer area completely using an applicator on the peristomal skin, repeating this process every day for 14 consecutive days. The control group received the usual Stoma Center instructions (using chamomile ointment). The study compared the impact of topical solution of Scrophularia Striata on Ostomy Skin Tool to assess ulcer-healing progress between the two groups. The analysis revealed that on the 21 days post-intervention. The wound ulcer improvement in the experimental group was significantly greater than in the control group (p < 0.001). The results of the study indicate that the topical solution of Scrophularia Striata has been effective and more efficient in improving peristomal skin wounds compared to other routine treatments in these patients. Considering the impact of this solution on peristomal skin ulcer healing, its use is recommended. © 2025 The Author(s). International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.

08
CLINICAL STUDY Menopause (New York, N.Y.) (2025) PMID: 39836709 ↗
Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial.
Clinical Trial Synthesis 2025 Clinical Study published in Menopause (New York, N.Y.); statistical significance reported at p = 0.001. Key conclusion: CONCLUSIONS: Chamomile intervention shows promise in alleviating menopausal symptoms, but its use warrants caution due to associated side effects.
View Original PubMed Abstract ↓

OBJECTIVE: Menopausal symptoms can significantly impact women's quality of life. Herbal interventions like Matricaria chamomilla (chamomile) have been suggested as potential remedies. However, their efficacy and safety remain underexplored. METHODS: This triple-blind clinical trial enrolled 80 postmenopausal women meeting specific criteria. Inclusion criteria included participants in early or late perimenopause, defined by a symptom score >15, FSH levels >40, or 2 years since menopause, with no significant comorbidities. Participants were randomly assigned to intervention and placebo groups. In a triple-blind clinical trial with 80 postmenopausal women (aged 47-62) from Babol City Health Center, participants were randomly assigned to receive either chamomile (100 mg capsules with 1.2% apigenin, four times daily) or a placebo over 12 weeks. Symptoms of menopause were assessed using the Australian Menopause Association's Scorecard Symptom Questionnaire. Over 12 weeks, they received either chamomile or placebo capsules, with side effect assessments every 4 weeks. RESULTS: Notable differences were found between the intervention and control groups in the overall scores on the symptom scorecard from baseline to 12 weeks' postintervention (-10.36; 95% confidence interval [CI], -13.84 to -6.92; P < 0.001). Specific subscores also improved in the intervention group: vasomotor (-2.25; 95% CI, -3.09 to -1.42; P < 0.001), psychological (-3.74; 95% CI, -5.29 to -2.20; P < 0.001), locomotor (-2.70; 95% CI, -3.63 to -1.77; P < 0.001), and urological (-1.89; 95% CI, -2.77 to -1.00; P < 0.001). Both groups showed significant changes in total symptom scores over time ( P < 0.001). Two participants experienced side effects, including mouth sores, skin spots, and itching, in the chamomile group, which led to their dropping out of the study. CONCLUSIONS: Chamomile intervention shows promise in alleviating menopausal symptoms, but its use warrants caution due to associated side effects. Further research is necessary to optimize dosage and mitigate adverse reactions for safer and more effective management of menopausal symptoms.

09
RANDOMIZED TRIAL (RCT) Lymphatic research and biology (2025) PMID: 39723456 ↗
Effect of Chamomile and Olive Oils on Volume, Range of Motion, and Quality of Life in Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Lymphatic research and biology involving n = 63 participants; statistical significance reported at p = 0.05. Key conclusion: Conclusions: Chamomile and olive oils are tolerable for BCSs with BCRL; however, adding this intervention to CDT seems to have no superiority to CDT alone.
View Original PubMed Abstract ↓

Background: Lymphedema is one of the disturbing complications after breast cancer treatment that may affect the quality of life (QoL) of breast cancer survivors (BCSs). Methods: In this double-blind randomized clinical trial, 63 patients with breast cancer-related lymphedema (BCRL) were included in the study. Group A received standard complete decongestive therapy (CDT), group B received CDT with olive oil, and group C received CDT with chamomile and olive oil. Lymphedema volume and range of motion (RoM) were measured at the beginning of the study and at sessions 7, 14, and 21. Patients' QoL was measured using the Short Form 36 questionnaire at baseline, at the end of the trial, and 1 month after the trial. For statistical analysis, SPSS software with a significance level of p < 0.05 was used. Results: The mean age of patients was 55.4 ± 10.1 years. Although the volume of lymphedema was reduced and RoM was increased in all groups, there was no significant difference between the three groups. However, the change in volume and RoM was more evident in group C. Moreover, the effect of interventions on health-related QoL dimensions in all groups was not statistically significant. However, in some dimensions, the score did not decrease in group B during follow-up. Conclusions: Chamomile and olive oils are tolerable for BCSs with BCRL; however, adding this intervention to CDT seems to have no superiority to CDT alone.

10
RANDOMIZED TRIAL (RCT) International journal of psychiatry in medicine (2025) PMID: 39545336 ↗
Effects of chamomile oil inhalation on sleep quality in young adults with insomnia: A randomized controlled trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in International journal of psychiatry in medicine involving n = 40 participants; statistical significance reported at p = 0.001. Key conclusion: No participant in either group reported adverse events during or after the study.ConclusionFifteen days of chamomile oil inhalation before bedtime reduced insomnia severity and enhanced the quality of sleep for young adults suffering from insomnia.
View Original PubMed Abstract ↓

ObjectiveInsomnia is characterized by difficulty falling asleep, staying sleep, or both. Aromatherapy is a commonly used complementary and alternative medicine practice by persons with insomnia. Previous studies have shown that use of chamomile oil during massage therapy improves the quality of sleep (QoS). However, to our knowledge, no randomized controlled trials have examined the effects of chamomile oil inhalation on the treatment of insomnia. The present study evaluated the effect of chamomile oil inhalation on QoS and insomnia severity in persons with insomnia.MethodsA total of 80 participants ages 18-35 with insomnia were randomly assigned to aromatherapy group (AG; n = 40) or a control group (CG; n = 40). Those in the AG group received chamomile oil inhalation, while those in the CG group engaged in their normal routine for 10 minutes a day, daily for 15 days. The Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) were administered before and after the intervention.ResultsWithin-group analysis showed a significant reduction both in PSQI and ISI scores among those in the AG (P < 0.001 for both scores), whereas the CG reported a significant reduction in PSQI score (P = 0.033) and no significant changes in ISI score (P = 0.068). The between-group analysis after the intervention demonstrated a significant reduction in PSQI and ISI scores in the AG group (P < 0.001 for both) compared to the CG group. No participant in either group reported adverse events during or after the study.ConclusionFifteen days of chamomile oil inhalation before bedtime reduced insomnia severity and enhanced the quality of sleep for young adults suffering from insomnia. Further studies are needed to replicate the results of this study using an active control group.

RELATED MONOGRAPHS

Related Monographs in This Category